Townsendbullock8316

It also shows how conditions surrounding the innovation both enabled its development and inhibited its wider scale-up.

By recognizing that technological artefacts can simultaneously enable and inhibit collaboration, this paper highlights the need to overcome tensions between the transformative capability of such healthcare innovations and the inhibiting effects simultaneously created on change at a wider system level.

By recognizing that technological artefacts can simultaneously enable and inhibit collaboration, this paper highlights the need to overcome tensions between the transformative capability of such healthcare innovations and the inhibiting effects simultaneously created on change at a wider system level.

Parallel phase-shifting digital holographic microscope (PPSDHM) is powerful for three-dimensional (3D) measurements of dynamic specimens. However, the PPSDHM reported previously was directly fixed on the optical bench and imposed difficulties case, thus it is required to modify the specification of the microscope or transport the microscope to another location.

We present a modularized PPSDHM. We construct the proposed PPSDHM and demonstrate the 3D measurement capability of the PPSDHM.

The PPSDHM was designed as an inverted microscope to record transparent objects and modularized by integrating the optical elements of the PPSDHM on an optical breadboard. To demonstrate the effectiveness of the PPSDHM, we recorded a 3D motion-picture of moving Volvoxes at 1000  frames  /  s and carried out 3D tracking of the Volvoxes.

The PPSDHM was practically realized and 3D images of objects were successfully reconstructed from holograms recorded with a single-shot exposure. The 3D trajectories of Volvoxes were obtained from the reconstructed images.

We established a modularized PPSDHM that is capable of 3D image acquisition by integrating the optical elements of the PPSDHM on an optical breadboard. The recording capability of 3D motion-pictures of dynamic specimens was experimentally demonstrated by the PPSDHM.

We established a modularized PPSDHM that is capable of 3D image acquisition by integrating the optical elements of the PPSDHM on an optical breadboard. The recording capability of 3D motion-pictures of dynamic specimens was experimentally demonstrated by the PPSDHM.The prevalence of pancreatic ductal adenocarcinoma (PDAC) is increasing in the western world, being currently on of the leading causes of mortality. Surgical resection provides best chances of cure but, unfortunately, less than 20% of the patients are eligible for curative intent surgery at the time of diagnosis. Chemotherapeutic agents such as FOLFIRINOX have been used in patients with metastatic or locally advanced disease showing survival benefit.

In this pilot study, we present an early initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced and non resectable PDAC highlighting the toxicity and complete resection rates as well as overall survival.

Roughly every patient experienced toxicity according to ECOG criteria with a median recorded event up to 6, most of them grade I and grade II. One third of the patients had downsizing of tumor, however only 43.3% of them ended up having resectable disease. A R0 resection was achieved in 10 of the patients (76.9%). Median follow up for the entire study was 14 months. Fourteen patients (46.6%) had stable disease and 7 (23.3%) had tumor-related death. Approximately 30% of the patients were in remission by the end of follow up. Considering the above results patients that had good response to FOLFIRINOX and underwent R0 surgical treatment had increased their median survival to 30 months compared to those who did not have oncological tumor resection (13 months).

FOLFIRINOX is an effective treatment regimen that manages to convert unresectable -at diagnosis PDAC- to resectable with increased survival. However, due to high toxicity, treatment is only feasible in selected patients and requires close monitoring.

FOLFIRINOX is an effective treatment regimen that manages to convert unresectable -at diagnosis PDAC- to resectable with increased survival. However, due to high toxicity, treatment is only feasible in selected patients and requires close monitoring.

To investigate the expression and clinical value of miR-27a in the serum of patients with skin squamous cell carcinoma.

70 patients with skin cancer diagnosed and treated in our hospital from July 2015 to July 2018 were selected as the experimental group, and 62 healthy patients with normal physical examination during the same period as the control group. The expression of miR-27a in serum of patients in both groups was detected by fluorogenic quantitative polymerase chain reaction (qRT-PCR). The expression levels of topoisomerase II (topo-II) and human epidermal growth factor receptor 2 (c-erbB-2) were detected by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve was used to analyze the predictive value of miR-27a for poor prognosis and the diagnostic value of miR-27a for skin squamous cell carcinoma.

The expression levels of miR-27a, topo-II and c-erbB-2 of patients in the experimental group were significantly higher than those of the control group (p<0.001). The 3-year survival rate in the low miR-27a expression group was higher than that of the high expression group. The sensitivity, specificity and AUC of serum miR-27a in predicting the prognosis of skin cancer were 60.71%, 92.86%, 0.765, respectively.

The expression of miR-27a in tissue and serum was higher in patients with skin squamous cell carcinoma compared with healthy controls and was closely related to some pathological data of skin cancer. This miR can be used as a detection marker for screening and diagnosing skin squamous cell carcinoma and has a certain predictive value for prognosis.

The expression of miR-27a in tissue and serum was higher in patients with skin squamous cell carcinoma compared with healthy controls and was closely related to some pathological data of skin cancer. This miR can be used as a detection marker for screening and diagnosing skin squamous cell carcinoma and has a certain predictive value for prognosis.

Retinoblastoma causes significant human mortality especially in children. Although retinoblastoma may be treated if detected at early stage, however, it becomes destructive at advanced stages. The treatment involves surgery and chemotherapy. However, the chemotherapeutic agents have severe adverse effects. Therefore, development of viable drugs and identification of novel molecular therapeutic targets may enable efficient management of retinoblastoma. This study was designed to examine the expression profile of Chromatin Assembly Factor-1 (CHAF1A) and explore its therapeutic implications in retinoblastoma.

The expression of CHAF1A was determined by qRT-PCR. MTT assay was used for the determination of the cell viability. Apoptosis was detected by acridine orange (AO)/ethidium bromide (EB) and annexin V/propidium iodide (PI) assay. Cell cycle analysis was determined by flow cytometery. Protein expression was determined by western blot analysis.

The results showed that CHAF1A is significantly upregulated iastoma.

We aimed to evaluate the role of repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of patients with recurrent peritoneal metastatic disease (PM) with special consideration to perioperative outcomes and long-term survival outcomes.

Patients with recurrent PM who underwent CRS and HIPEC for the management of the disease for an interval of 15 years were retrospectively analyzed. Primary tumor location, peritoneal cancer index, completeness of cytoreduction (CC), morbidity, mortality, overall survival (OS), and progression-free survival (PFS) after the 1st and 2nd HIPEC were assessed.

A total of 48 patients who underwent repeat CRS and HIPEC for the management of disease relapse were included in this study. The median OS from initial diagnosis was 37 months (range 12-128) while the PFS after the second CRS and HIPEC was 12 months (range 0-36). A total of 30 complications were recorded among which 18.8% were classified as major. CC-0 resection was a significant indicator of survival either on univariate or on multivariate analysis.

The outcomes of the present study indicate the feasibility of repeat CRS and HIPEC procedures in patients with recurrent peritoneal metastasis with significant morbidity, acceptable mortality and long-term survival outcomes which were highly associated with CC status.

The outcomes of the present study indicate the feasibility of repeat CRS and HIPEC procedures in patients with recurrent peritoneal metastasis with significant morbidity, acceptable mortality and long-term survival outcomes which were highly associated with CC status.

Thymoma is a thymic epithelial tumor characterized by the presence of epithelial cells and lymphocytes in the thymus. Although the incidence of thymoma is not high, we know very little about its treatment mechanism. Therefore, this study was intended to explore its potential targets and provide a new approach for perfect targeted therapy.

We identified a series of non-coding (nc) RNAs (including BCL11A, miR-3977, miR-4460 and miR-542-3p) and TF (FAM185A, MGAM2, SEC14L4, ACTBL2), and predicted transcription factors (including AHR, ATF4, CEBPA and DDIT3) that have significant regulatory effects on the module by difference analysis, co-expression analysis, enrichment analysis of thymoma gene expression profiling and using hypergeometric test to calculate the potential regulatory effects of multiple factors on the module.

We obtained 15 modules from the thymoma dysfunction modules and found that the module genes are involved in a variety of immune-related biological functions. Homoharringtonine nmr For example, neutrophil activation involved in immune response, neutrophil mediated immunity and response to extracellular stimulus indicate that neutrophil-mediated regulation plays an important regulatory role in the thymoma disorder module.

Overall, a dysfunction module for thymoma was identified, and significant pivotal regulators in the module were used as important components of thymoma molecular dysregulation, of which ACTBL2 could serve as a potential therapeutic target in thymoma, which provides an effective theoretical reference for subsequent researchers.

Overall, a dysfunction module for thymoma was identified, and significant pivotal regulators in the module were used as important components of thymoma molecular dysregulation, of which ACTBL2 could serve as a potential therapeutic target in thymoma, which provides an effective theoretical reference for subsequent researchers.

To determine whether there is a relationship between maximum standardized uptake (SUVmax) value of basal 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) that was performed before sunitinib treatment and treatment-related survival in patients with metastatic renal cell carcinoma (mRCC).

The data of 36 patients (female/male 1/1, median age 57.36 years, range 31-74) were retrospectively analyzed in whom sunitinib treatment was started due to mRCC between 2008 and 2019 and who underwent basal 18F-FDG PET/CT examination before this treatment. The median SUVmax value was 6.8. Progression-free survival (PFS) and overall survival (OS) rates of patients, who had SUVmax value >6.8 (group I) (50%, n=18) and ≤ than 6.8 (group II) (50%, n=18), were compared.

Both PFS and OS were significantly lower in the group with high SUVmax (SUVmax> 6.8, group I) before the sunitinib treatment than the group with low SUVmax (SUVmax ≤6.8, group II). When patients with SUVmax value> 6.